Literature DB >> 24762227

Synergistic antitumoral effect of IL-12 gene cotransfected with antiangiogenic genes for angiostatin, endostatin, and saxatilin.

Hong Sung Kim1, Hwa Yeon Jeong, Yeon Kyung Lee, Keun Sik Kim, Yong Serk Park.   

Abstract

Previously, it was reported that the cotransfection of angiostatin K1-3, endostatin, and saxatilin genes using cationic liposomes significantly inhibited tumor progression. IL-12 is a well-known immune modulator that promotes Th1-type antitumor immune responses and also induces antiangiogenic effects. In this study, we have examined the antitumoral function of the IL-12 gene cotransfected with antiangiogenic genes for angiostatin K1-3, endostatin, and saxatilin by O,O'-dimyristyl-N-lysyl glutamate (DMKE) cationic liposomes in a mouse tumor model. According to our results, the administration of the IL-12 gene or the genes for angiostatin K1-3, endostatin, and saxatilin exhibited effective inhibition of B16BL6 melanoma growth in mice. In particular, intravenous administration of the IL-12 gene along with intratumoral administration of the three antiangiogenic genes synergistically inhibited the B16BL6 tumor growth. These results suggest that systemically expressed IL-12 enhances antitumoral efficacy of locally expressed antiangiogenic proteins.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24762227     DOI: 10.3727/096504014X13907540404798

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  2 in total

1.  Cancer-targeted Nucleic Acid Delivery and Quantum Dot Imaging Using EGF Receptor Aptamer-conjugated Lipid Nanoparticles.

Authors:  Min Woo Kim; Hwa Yeon Jeong; Seong Jae Kang; Moon Jung Choi; Young Myoung You; Chan Su Im; Tae Sup Lee; In Ho Song; Chang Gun Lee; Ki-Jong Rhee; Yeon Kyung Lee; Yong Serk Park
Journal:  Sci Rep       Date:  2017-08-25       Impact factor: 4.379

Review 2.  Tumor angiogenesis and anti-angiogenic gene therapy for cancer.

Authors:  Tinglu Li; Guangbo Kang; Tingyue Wang; He Huang
Journal:  Oncol Lett       Date:  2018-05-17       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.